Pulmonary arterial hypertension in congenital heart disease: Translational opportunities to study the reversibility of pulmonary vascular disease

European Heart Journal

Volumn 38, Issue 26, 2017, Pages 2034-2040

  Van Der Feen, Diederik E ^a   Bartelds, B ^a   De Boer, Rudolf A ^b   Berger, Rolf M F ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Congenital heart disease; Neointimal plexiform lesions; Operability; Pulmonary blood flow; Reversible irreversible; Vascular remodelling

Indexed keywords

BONE MORPHOGENETIC PROTEIN; TRANSFORMING GROWTH FACTOR BETA; ANTIHYPERTENSIVE AGENT;

APOPTOSIS; CONGENITAL HEART DISEASE; DISEASE COURSE; HUMAN; INFLAMMATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SIGNAL TRANSDUCTION; VASCULAR REMODELING; ADULT; ANIMAL; CHILD; COMPLICATION; CONGENITAL HEART MALFORMATION; DISEASE EXACERBATION; DISEASE MODEL; LUNG CIRCULATION; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULITIS;

ADULT; ANIMALS; ANTIHYPERTENSIVE AGENTS; APOPTOSIS; BONE MORPHOGENETIC PROTEINS; CHILD; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HEART DEFECTS, CONGENITAL; HUMANS; HYPERTENSION, PULMONARY; PULMONARY CIRCULATION; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; VASCULAR REMODELING; VASCULITIS;

EID: 85026554051     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehx034     Document Type: Review

References (76)

1. Stacher E, Graham BB, Hunt JM, Gandjeva A, Groshong SD, McLaughlin VV, Jessup M, Grizzle WE, Aldred MA, Cool CD, Tuder RM. Modern age pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med 2012;186:261-272.
2. Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, Langleben D, Manes A, Satoh T, Torres F, Wilkins MR, Badesch DB. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013;62(25 Suppl):D42-D50.
3. Galie N, Corris PA, Frost A, Girgis RE, Granton J, Jing ZC, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 2013;62(25 Suppl):D60-D72.
4. Wagenvoort CA, Wagenvoort N, Draulans-Noe Y. Reversibility of plexogenic pulmonary arteriopathy following banding of the pulmonary artery. J Thorac Cardiovasc Surg 1984;87:876-886.
5. Heath D, Edwards JE. The pathology of hypertensive pulmonary vascular disease: a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation 1958;18(4 Part 1):533-547.
6. Dickinson MG, Bartelds B, Borgdorff MA, Berger RM. The role of disturbed blood flow in the development of pulmonary arterial hypertension: lessons from preclinical animal models. Am J Physiol Lung Cell Mol Physiol 2013;305:L1-L14.
7. Tuder RM, Archer SL, Dorfmuller P, Erzurum SC, Guignabert C, Michelakis E, Rabinovitch M, Schermuly R, Stenmark KR, Morrell NW. Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol 2013;62(25 Suppl):D4-D12.
8. Hoffman JI, Rudolph AM, Heymann MA. Pulmonary vascular disease with congenital heart lesions: pathologic features and causes. Circulation 1981;64:873-877.
9. Levy M, Maurey C, Celermajer DS, Vouhe PR, Danel C, Bonnet D, Israel-Biet D. Impaired apoptosis of pulmonary endothelial cells is associated with intimal proliferation and irreversibility of pulmonary hypertension in congenital heart disease. J Am Coll Cardiol 2007;49:803-810.
10. Manes A, Palazzini M, Leci E, Bacchi Reggiani ML, Branzi A, Galie N. Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups. Eur Heart J 2014;35:716-724.
11. D'alto M, Romeo E, Argiento P, Correra A, Santoro G, Gaio G, Sarubbi B, Calabro R, Russo MG. Hemodynamics of patients developing pulmonary arterial hypertension after shunt closure. Int J Cardiol 2013;168:3797-3801.
12. Wagenvoort CA. Open lung biopsies in congenital heart disease for evaluation of pulmonary vascular disease: predictive value with regard to corrective operability. Histopathology 1985;9:417-436.
13. Haworth SG. Pulmonary vascular disease in ventricular septal defect: structural and functional correlations in lung biopsies from 85 patients, with outcome of intracardiac repair. J Pathol 1987;152:157-168.
14. dos Santos Fernandes CJ, Jardim CV, Hovnanian A, Hoette S, Dias BA, Souza S, Humbert M, Souza R. Survival in schistosomiasis-associated pulmonary arterial hypertension. J Am Coll Cardiol 2010;56:715-720.
15. Hong JH, Lee SE, Choi SY, Kim SH, Jang EJ, Bang JH, Park JE, Jeon HR, Oh YJ, Yi JE, Jung HO, Youn HJ, Kim DW. Reversible pulmonary arterial hypertension associated with dasatinib for chronic myeloid leukemia. Cancer Res Treat 2015;47:937-942.
16. Limsuwan A, Pakakasama S, Hongeng S. Reversible course of pulmonary arterial hypertension related to bone marrow transplantation. Heart Vessels 2011;26:557-561.
17. van Albada ME, Schoemaker RG, Kemna MS, Cromme-Dijkhuis AH, van Veghel R, Berger RM. The role of increased pulmonary blood flow in pulmonary arterial hypertension. Eur Respir J 2005;26:487-493.
18. Haworth SG. Pulmonary vascular disease in different types of congenital heart disease: implications for interpretation of lung biopsy findings in early childhood. Br Heart J 1984;52:557-571.
19. Kulik TJ. Pulmonary blood flow and pulmonary hypertension: is the pulmonary circulation flowophobic or flowophilic?. Pulm Circ 2012;2:327-339.
20. van Albada ME, Berger RM. Pulmonary arterial hypertension in congenital cardiac disease-the need for refinement of the Evian-Venice classification. Cardiol Young 2008;18:10-17.
21. van Loon RL, Roofthooft MT, Hillege HL, ten Harkel AD, van Osch-Gevers M, Delhaas T, Kapusta L, Strengers JL, Rammeloo L, Clur SA, Mulder BJ, Berger RM. Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005. Circulation 2011;124:1755-1764.
22. van Riel AC, Schuuring MJ, van Hessen ID, Zwinderman AH, Cozijnsen L, Reichert CL, Hoorntje JC, Wagenaar LJ, Post MC, van Dijk AP, Hoendermis ES, Mulder BJ, Bouma BJ. Contemporary prevalence of pulmonary arterial hypertension in adult congenital heart disease following the updated clinical classification. Int J Cardiol 2014;174:299-305.
23. Engelfriet PM, Duffels MG, Moller T, Boersma E, Tijssen JG, Thaulow E, Gatzoulis MA, Mulder BJ. Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease. Heart 2007;93:682-687.
24. van Loon RL, Roofthooft MT, van Osch-Gevers M, Delhaas T, Strengers JL, Blom NA, Backx A, Berger RM. Clinical characterization of pediatric pulmonary hypertension: complex presentation and diagnosis. J Pediatr 2009;155:176-182.e1.
25. Levy MM. Genetic analyses in a cohort of children with pulmonary hypertension. Eur Resp J 2016(10);48:1118-1126.
26. Roofthooft MT, Bergman KA, Waterbolk TW, Ebels T, Bartelds B, Berger RM. Persistent pulmonary hypertension of the newborn with transposition of the great arteries. Ann Thorac Surg 2007;83:1446-1450.
27. Haworth SG, Hislop AA. Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001-2006. Heart 2009;95:312-317.
28. van de Veerdonk MCMC. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol 2011(12-6);58:2511.
29. Berger RM, Beghetti M, Humpl T, Raskob GE, Ivy DD, Jing ZC, Bonnet D, Schulze-Neick I, Barst RJ. Clinical features of paediatric pulmonary hypertension: a registry study. Lancet 2012;379:537-546.
30. Moulton MJ, Creswell LL, Ungacta FF, Downing SW, Szabó BA, Pasque MK. Magnetic resonance imaging provides evidence for remodeling of the right ventricle after single-lung transplantation for pulmonary hypertension. Circulation 1996;94:II312-II319.
31. Zijlstra WM, Douwes JM, Rosenzweig EB, Schokker S, Krishnan U, Roofthooft MT, Miller-Reed K, Hillege HL, Ivy DD, Berger RM. Survival differences in pediatric pulmonary arterial hypertension: clues to a better understanding of outcome and optimal treatment strategies. J Am Coll Cardiol 2014;63:2159-2169.
32. Barst RJ, Ivy DD, Foreman AJ, McGoon MD, Rosenzweig EB. Four- and seven-year outcomes of patients with congenital heart disease-associated pulmonary arterial hypertension (from the REVEAL Registry). Am J Cardiol 2014;113:147-155.
33. Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M, Aboyans V, Vaz Carneiro A, Achenbach S, Agewall S, Allanore Y, Asteggiano R, Paolo Badano L, Albert Barbera J, Bouvaist H, Bueno H, Byrne RA, Carerj S, Castro G, Erol C, Falk V, Funck-Brentano C, Gorenflo M, Granton J, Iung B, Kiely DG, Kirchhof P, Kjellstrom B, Landmesser U, Lekakis J, Lionis C, Lip GY, Orfanos SE, Park MH, Piepoli MF, Ponikowski P, Revel MP, Rigau D, Rosenkranz S, Voller H, Luis Zamorano J. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2016;37:67-119.
34. Dammann JF Jr, Ferencz C. The significance of the pulmonary vascular bed in congenital heart disease. I. Normal lungs. II. Malformations of the heart in which there is pulmonary stenosis. Am Heart J 1956;52:7-17.
35. Wagenvoort CA, Neufeld HN, Dushane JW, Edwards JE. The pulmonary arterial tree in ventricular septal defect: a quantitative study of anatomic features in fetuses, infants and children. Circulation 1961;23:740-748.
36. Haworth SGSG. A morphometric study of regional variation in lung structure in infants with pulmonary hypertension and congenital cardiac defect: a justification of lung biopsy. Br Heart J 1978-8;40:825-831.
37. Wilson NJ, Seear MD, Taylor GP, LeBlanc JG, Sandor GG. The clinical value and risks of lung biopsy in children with congenital heart disease. J Thorac Cardiovasc Surg 1990;99:460-468.
38. Egito ES, Aiello VD, Bosisio IB, Lichtenfels AJ, Horta AL, Saldiva PH, Capelozzi VL. Vascular remodeling process in reversibility of pulmonary arterial hypertension secondary to congenital heart disease. Pathol Res Pract 2003;199:521-532.
39. O'blenes SB, Fischer S, McIntyre B, Keshavjee S, Rabinovitch M. Hemodynamic unloading leads to regression of pulmonary vascular disease in rats. J Thorac Cardiovasc Surg 2001;121:279-289.
40. Mercier O, Sage E, de Perrot M, Tu L, Marcos E, Decante B, Baudet B, Herve P, Dartevelle P, Eddahibi S, Fadel E. Regression of flow-induced pulmonary arterial vasculopathy after flow correction in piglets. J Thorac Cardiovasc Surg 2009;137:1538-1546.
41. Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, McMahon G, Waltenberger J, Voelkel NF, Tuder RM. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. Faseb J 2001;15:427-438.
42. Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 2009;297:L1013-L1032.
43. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, Gomez Sanchez MA, Krishna Kumar R, Landzberg M, Machado RF, Olschewski H, Robbins IM, Souza R. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013;62(25 Suppl):D34-D41.
44. van der Feen DE, Dickinson MG, Bartelds B, Borgdorff MAJ, Sietsma H, Lévy M, Sietsma H, Berger RMF. Egr-1 Identifies neointimal remodeling and relates to progression in human pulmonary arterial hypertension. J Heart Lung Transplant 2016;35(4):481-490.
45. Best MG, Sol N, Kooi I, Tannous J, Westerman BA, Rustenburg F, Schellen P, Verschueren H, Post E, Koster J, Ylstra B, Ameziane N, Dorsman J, Smit EF, Verheul HM, Noske DP, Reijneveld JC, Nilsson RJ, Tannous BA, Wesseling P, Wurdinger T. RNA-Seq of tumor-educated platelets enables blood-based pancancer, multiclass, and molecular pathway cancer diagnostics. Cancer Cell 2015;28:666-676.
46. Smadja DM, Gaussem P, Mauge L, Israel-Biet D, Dignat-George F, Peyrard S, Agnoletti G, Vouhe PR, Bonnet D, Levy M. Circulating endothelial cells: a new candidate biomarker of irreversible pulmonary hypertension secondary to congenital heart disease. Circulation 2009;119:374-381.
47. McMurtry MS, Archer SL, Altieri DC, Bonnet S, Haromy A, Harry G, Bonnet S, Puttagunta L, Michelakis ED. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest 2005;115:1479-1491.
48. Sakao S, Taraseviciene-Stewart L, Lee JD, Wood K, Cool CD, Voelkel NF. Initial apoptosis is followed by increased proliferation of apoptosis-resistant endothelial cells. Faseb J 2005;19:1178-1180.
49. Dickinson MG, Kowalski PS, Bartelds B, Borgdorff MA, van der Feen D, Sietsma H, Molema G, Kamps JA, Berger RM. A critical role for Egr-1 during vascular remodelling in pulmonary arterial hypertension. Cardiovasc Res 2014;103(4):573-584.
50. Meloche J, Potus F, Vaillancourt M, Bourgeois A, Johnson I, Deschamps L, Chabot S, Ruffenach G, Henry S, Breuils-Bonnet S, Tremblay E, Nadeau V, Lambert C, Paradis R, Provencher S, Bonnet S. Bromodomain-containing protein 4: the epigenetic origin of pulmonary arterial hypertension. Circ Res 2015(Aug. 28);117:525-535.
51. Dickinson MG, Bartelds B, Molema G, Borgdorff MA, Boersma B, Takens J, Weij M, Wichers P, Sietsma H, Berger RM. Egr-1 expression during neointimal development in flow-associated pulmonary hypertension. Am J Pathol 2011;179:2199-2209.
52. Soon E, Holmes AM, Treacy CM, Doughty NJ, Southgate L, Machado RD, Trembath RC, Jennings S, Barker L, Nicklin P, Walker C, Budd DC, Pepke-Zaba J, Morrell NW. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation 2010;122:920-927.
53. Selimovic N, Bergh CH, Andersson B, Sakiniene E, Carlsten H, Rundqvist B. Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension. Eur Respir J 2009 Sep; 34:662-668.
54. Price LC, Wort SJ, Perros F, Dorfmuller P, Huertas A, Montani D, Cohen-Kaminsky S, Humbert M. Inflammation in pulmonary arterial hypertension. Chest 2012;141:210-221.
55. Rabinovitch M, Guignabert C, Humbert M, Nicolls MR. Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. Circ Res 2014;115:165-175.
56. Steiner MK, Syrkina OL, Kolliputi N, Mark EJ, Hales CA, Waxman AB. Interleukin-6 overexpression induces pulmonary hypertension. Circ Res 2009;104:236-244, 28p following 244.
57. Crosby AA. Praziquantel reverses pulmonary hypertension and vascular remodeling in murine schistosomiasis. Am J Respir Crit Care Med 2011;184:467-473.
58. Bartelds B, van Loon RL, Mohaupt S, Wijnberg H, Dickinson MG, Boersma B, Takens J, van Albada M, Berger RM. Mast cell inhibition improves pulmonary vascular remodeling in pulmonary hypertension. Chest 2012;141:651-660.
59. Upton PDPD. The transforming growth factor-b-bone morphogenetic protein type signalling pathway in pulmonary vascular homeostasis and disease. Exp Physiol 2013;98:1262-1266.
60. Lane K, Machado R, Pauciulo M, Thomson J, Phillips J, Loyd J, Nichols W, Trembath R. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 2000;26:81-84.
61. Machado RDRD. Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. Hum Mutat 2006;27:121-132.
62. Atkinson Carl C. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 2002;105:1672-1678.
63. Graham Brian BBB. Transforming growth factor-b signaling promotes pulmonary hypertension caused by Schistosoma mansoni. Circulation 2013;128:1354-1364.
64. Gilbane Adrian JAJ. Impaired bone morphogenetic protein receptor II signaling in a transforming growth factor-b-dependent mouse model of pulmonary hypertension and in systemic sclerosis. Am J Respir Crit Care Med 2015;191:665-677.
65. Gao Bao-Hui BH. Expression and pathological implication of transforming growth factor-beta1 mRNA and endothelin-1 mRNA in intraacinar pulmonary arterioles of congenital heart disease accompanied with pulmonary hypertension. Zhonghua Bing Li Xue Za Zhi 2005;34:159-162.
66. Dalvi Pranjali P. Downregulation of bone morphogenetic protein receptor axis during HIV-1 and cocaine-mediated pulmonary smooth muscle hyperplasia: implications for HIV-related pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 2013;33:2585-2595.
67. Trembath RCRC. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2001;345:325-334.
68. Ranchoux B, Antigny F, Rucker-Martin C, Hautefort A, Pechoux C, Bogaard HJ, Dorfmuller P, Remy S, Lecerf F, Plante S, Chat S, Fadel E, Houssaini A, Anegon I, Adnot S, Simonneau G, Humbert M, Cohen-Kaminsky S, Perros F. Endothelialtomesenchymal transition in pulmonary hypertension. Circulation 2015;131:1006-1018
69. Spiekerkoetter EE. FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension. J Clin Invest 2013;123:3600-3613.
70. Long Lu L. Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension. Nat Med 2015;21:777-785.
71. Nasim Md Talat MT. BMPR-II deficiency elicits pro-proliferative and antiapoptotic responses through the activation of TGFb-TAK1-MAPK pathways in PAH. Hum Mol Genet 2012-6-1;21:2548-2558.
72. Nickel Nils N. GDF-15 is abundantly expressed in plexiform lesions in patients with pulmonary arterial hypertension and affects proliferation and apoptosis of pulmonary endothelial cells. Resp Res 2011;12:62.
73. Davies Rachel JRJ. BMP type II receptor deficiency confers resistance to growth inhibition by TGF-b in pulmonary artery smooth muscle cells: role of proinflammatory cytokines. Amer J Physiol Lung Cell Mol Physiol 2012 (15 Mar); 302:604-615.
74. Soon Elaine E. BMPR-II deficiency promotes pulmonary hypertension via increased inflammatory cytokine production. Am J Respir Crit Care Med 2015;192:859-872.
75. Spiekerkoetter E, Sung YK, Sudheendra D, Bill M, Aldred MA, van de Veerdonk MC, Vonk Noordegraaf A, Long-Boyle J, Dash R, Yang PC, Lawrie A, Swift AJ, Rabinovitch M, Zamanian RT. Low-dose FK506 (Tacrolimus) in end-stage pulmonary arterial hypertension. Am J Respir Crit Care Med 2015;192:254-257.
76. Nickel NP, Spiekerkoetter E, Gu M, Li CG, Li H, Kaschwich M, Diebold I, Hennigs JK, Kim KY, Miyagawa K, Wang L, Cao A, Sa S, Jiang X, Stockstill RW, Nicolls MR, Zamanian RT, Bland RD, Rabinovitch M. Elafin Reverses pulmonary hypertension via caveolin-1-dependent bone morphogenetic protein signaling. Am J Respir Crit Care Med 2015;191:1273-1286.